Congratulations to Charles Earnshaw, former Institute Clinical Fellow, who was invited to exhibit his research in Parliament as part of the STEM for Britain event. It was a great opportunity for Charles to discuss the important cancer research work being done in our Institute with different Members of Parliament.

Clinical Fellow Charles Earnshaw has been awarded the 2024 Edith Paterson Prize in recognition of the impressive scientific achievements made during his PhD studies.

Authors show that activating NF-κB allows MOMP to exert additional signalling functions besides triggering cell death. Findings support a rationale for engaging caspase-independent cell death in cell-killing anti-cancer therapies.

The secreted gelsolin component of the plasma actin-scavenging system impairs the ability of the receptor DNGR-1 to recognize dead cells and selectively dampens cross-presentation of tumor antigens by type 1 dendritic cells, acting as a barrier to anti-tumor immunity.

The gut microbiome has been shown to modulate the response of cancer patients to therapy, but precisely how microbiota affect anticancer immunity is still being elucidated. Giampazolias et al. report that vitamin D bioavailability in mice influences the composition of the gut microbiome.

This year was a significant period for our Institute as we made the long-anticipated return to the Paterson Building, our brand-new research facility on the Christie NHS Foundation Trust site. Find out how our staff continued to excel in all aspects of Institute life and reconnected with the wider scientific community within the Manchester Cancer Research Centre.

Cytotoxic therapies, besides directly provoking cancer cell death, can also stimulate immune-dependent tumour growth control or paradoxically accelerate tumour progression. Here, the authors show that all chemotherapy drugs acutely upregulate COX-2 and PGE2 production in cancer cells with pre-existing COX-2 activity and, in doing so, fuel cancer immune escape post-treatment.